Management goals for type 1 Gaucher disease

An expert consensus document from the European working group on Gaucher disease

M. Biegstraaten, T. M. Cox, N. Belmatoug, M. G. Berger, T. Collin-Histed, S. Vom Dahl, M. Di Rocco, C. Fraga, F. Giona, P. Giraldo, M. Hasanhodzic, D. A. Hughes, P. O. Iversen, A. I. Kiewiet, E. Lukina, M. Machaczka, T. Marinakis, E. Mengel, G. M. Pastores, U. Plöckinger & 10 others H. Rosenbaum, C. Serratrice, A. Symeonidis, J. Szer, J. Timmerman, A. Tylki-Szymańska, M. Weisz Hubshman, D. I. Zafeiriou, A. Zimran, C. E.M. Hollak

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Gaucher Disease type 1 (GD1) is a lysosomal disorder that affects many systems. Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment. More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment. A new set of management goals for GD1 in which both trends are reflected is needed. To this end, a modified Delphi procedure among 25 experts was performed. Based on a literature review and with input from patients, 65 potential goals were formulated as statements. Consensus was considered to be reached when ≥ 75% of the participants agreed to include that specific statement in the management goals. There was agreement on 42 statements. In addition to the traditional goals concerning haematological, visceral and bone manifestations, improvement in quality of life, fatigue and social participation, as well as early detection of long-term complications or associated diseases were included. When applying this set of goals in medical practice, the clinical status of the individual patient should be taken into account.

Original languageEnglish
Pages (from-to)203-208
Number of pages6
JournalBlood Cells, Molecules, and Diseases
Volume68
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Gaucher Disease
Social Participation
Fatigue
Therapeutics
Quality of Life
Phenotype
Bone and Bones

Keywords

  • Delphi study
  • Gaucher disease
  • Management goals
  • PROMs
  • Therapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Hematology
  • Cell Biology

Cite this

Biegstraaten, M., Cox, T. M., Belmatoug, N., Berger, M. G., Collin-Histed, T., Vom Dahl, S., ... Hollak, C. E. M. (2018). Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease. Blood Cells, Molecules, and Diseases, 68, 203-208. https://doi.org/10.1016/j.bcmd.2016.10.008

Management goals for type 1 Gaucher disease : An expert consensus document from the European working group on Gaucher disease. / Biegstraaten, M.; Cox, T. M.; Belmatoug, N.; Berger, M. G.; Collin-Histed, T.; Vom Dahl, S.; Di Rocco, M.; Fraga, C.; Giona, F.; Giraldo, P.; Hasanhodzic, M.; Hughes, D. A.; Iversen, P. O.; Kiewiet, A. I.; Lukina, E.; Machaczka, M.; Marinakis, T.; Mengel, E.; Pastores, G. M.; Plöckinger, U.; Rosenbaum, H.; Serratrice, C.; Symeonidis, A.; Szer, J.; Timmerman, J.; Tylki-Szymańska, A.; Weisz Hubshman, M.; Zafeiriou, D. I.; Zimran, A.; Hollak, C. E.M.

In: Blood Cells, Molecules, and Diseases, Vol. 68, 01.02.2018, p. 203-208.

Research output: Contribution to journalArticle

Biegstraaten, M, Cox, TM, Belmatoug, N, Berger, MG, Collin-Histed, T, Vom Dahl, S, Di Rocco, M, Fraga, C, Giona, F, Giraldo, P, Hasanhodzic, M, Hughes, DA, Iversen, PO, Kiewiet, AI, Lukina, E, Machaczka, M, Marinakis, T, Mengel, E, Pastores, GM, Plöckinger, U, Rosenbaum, H, Serratrice, C, Symeonidis, A, Szer, J, Timmerman, J, Tylki-Szymańska, A, Weisz Hubshman, M, Zafeiriou, DI, Zimran, A & Hollak, CEM 2018, 'Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease', Blood Cells, Molecules, and Diseases, vol. 68, pp. 203-208. https://doi.org/10.1016/j.bcmd.2016.10.008
Biegstraaten, M. ; Cox, T. M. ; Belmatoug, N. ; Berger, M. G. ; Collin-Histed, T. ; Vom Dahl, S. ; Di Rocco, M. ; Fraga, C. ; Giona, F. ; Giraldo, P. ; Hasanhodzic, M. ; Hughes, D. A. ; Iversen, P. O. ; Kiewiet, A. I. ; Lukina, E. ; Machaczka, M. ; Marinakis, T. ; Mengel, E. ; Pastores, G. M. ; Plöckinger, U. ; Rosenbaum, H. ; Serratrice, C. ; Symeonidis, A. ; Szer, J. ; Timmerman, J. ; Tylki-Szymańska, A. ; Weisz Hubshman, M. ; Zafeiriou, D. I. ; Zimran, A. ; Hollak, C. E.M. / Management goals for type 1 Gaucher disease : An expert consensus document from the European working group on Gaucher disease. In: Blood Cells, Molecules, and Diseases. 2018 ; Vol. 68. pp. 203-208.
@article{03403e43a00b4031879a6bf6806dd8a6,
title = "Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease",
abstract = "Gaucher Disease type 1 (GD1) is a lysosomal disorder that affects many systems. Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment. More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment. A new set of management goals for GD1 in which both trends are reflected is needed. To this end, a modified Delphi procedure among 25 experts was performed. Based on a literature review and with input from patients, 65 potential goals were formulated as statements. Consensus was considered to be reached when ≥ 75{\%} of the participants agreed to include that specific statement in the management goals. There was agreement on 42 statements. In addition to the traditional goals concerning haematological, visceral and bone manifestations, improvement in quality of life, fatigue and social participation, as well as early detection of long-term complications or associated diseases were included. When applying this set of goals in medical practice, the clinical status of the individual patient should be taken into account.",
keywords = "Delphi study, Gaucher disease, Management goals, PROMs, Therapy",
author = "M. Biegstraaten and Cox, {T. M.} and N. Belmatoug and Berger, {M. G.} and T. Collin-Histed and {Vom Dahl}, S. and {Di Rocco}, M. and C. Fraga and F. Giona and P. Giraldo and M. Hasanhodzic and Hughes, {D. A.} and Iversen, {P. O.} and Kiewiet, {A. I.} and E. Lukina and M. Machaczka and T. Marinakis and E. Mengel and Pastores, {G. M.} and U. Pl{\"o}ckinger and H. Rosenbaum and C. Serratrice and A. Symeonidis and J. Szer and J. Timmerman and A. Tylki-Szymańska and {Weisz Hubshman}, M. and Zafeiriou, {D. I.} and A. Zimran and Hollak, {C. E.M.}",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.bcmd.2016.10.008",
language = "English",
volume = "68",
pages = "203--208",
journal = "Blood Cells, Molecules, and Diseases",
issn = "1079-9796",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Management goals for type 1 Gaucher disease

T2 - An expert consensus document from the European working group on Gaucher disease

AU - Biegstraaten, M.

AU - Cox, T. M.

AU - Belmatoug, N.

AU - Berger, M. G.

AU - Collin-Histed, T.

AU - Vom Dahl, S.

AU - Di Rocco, M.

AU - Fraga, C.

AU - Giona, F.

AU - Giraldo, P.

AU - Hasanhodzic, M.

AU - Hughes, D. A.

AU - Iversen, P. O.

AU - Kiewiet, A. I.

AU - Lukina, E.

AU - Machaczka, M.

AU - Marinakis, T.

AU - Mengel, E.

AU - Pastores, G. M.

AU - Plöckinger, U.

AU - Rosenbaum, H.

AU - Serratrice, C.

AU - Symeonidis, A.

AU - Szer, J.

AU - Timmerman, J.

AU - Tylki-Szymańska, A.

AU - Weisz Hubshman, M.

AU - Zafeiriou, D. I.

AU - Zimran, A.

AU - Hollak, C. E.M.

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Gaucher Disease type 1 (GD1) is a lysosomal disorder that affects many systems. Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment. More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment. A new set of management goals for GD1 in which both trends are reflected is needed. To this end, a modified Delphi procedure among 25 experts was performed. Based on a literature review and with input from patients, 65 potential goals were formulated as statements. Consensus was considered to be reached when ≥ 75% of the participants agreed to include that specific statement in the management goals. There was agreement on 42 statements. In addition to the traditional goals concerning haematological, visceral and bone manifestations, improvement in quality of life, fatigue and social participation, as well as early detection of long-term complications or associated diseases were included. When applying this set of goals in medical practice, the clinical status of the individual patient should be taken into account.

AB - Gaucher Disease type 1 (GD1) is a lysosomal disorder that affects many systems. Therapy improves the principal manifestations of the condition and, as a consequence, many patients show a modified phenotype which reflects manifestations of their disease that are refractory to treatment. More generally, it is increasingly recognised that information as to how a patient feels and functions [obtained by patient- reported outcome measurements (PROMs)] is critical to any comprehensive evaluation of treatment. A new set of management goals for GD1 in which both trends are reflected is needed. To this end, a modified Delphi procedure among 25 experts was performed. Based on a literature review and with input from patients, 65 potential goals were formulated as statements. Consensus was considered to be reached when ≥ 75% of the participants agreed to include that specific statement in the management goals. There was agreement on 42 statements. In addition to the traditional goals concerning haematological, visceral and bone manifestations, improvement in quality of life, fatigue and social participation, as well as early detection of long-term complications or associated diseases were included. When applying this set of goals in medical practice, the clinical status of the individual patient should be taken into account.

KW - Delphi study

KW - Gaucher disease

KW - Management goals

KW - PROMs

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85006057007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85006057007&partnerID=8YFLogxK

U2 - 10.1016/j.bcmd.2016.10.008

DO - 10.1016/j.bcmd.2016.10.008

M3 - Article

VL - 68

SP - 203

EP - 208

JO - Blood Cells, Molecules, and Diseases

JF - Blood Cells, Molecules, and Diseases

SN - 1079-9796

ER -